Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Grifols, Regeneron
April 25, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 25, 2024 (GLOBE NEWSWIRE) -- Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche,...
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts
April 25, 2024 07:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts John Davis brings direct clinical expertise as...
HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight
April 24, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the...
Gardner Syndrome Treatment Market Report 2024: Analysis and Forecast Through 2018-2033 Featuring Biochem Pharmaceuticals Industries, Zydus Lifesciences, Vernalis (R&D), Sun Pharmaceutical Industries, and Sanofi
April 24, 2024 04:09 ET
|
Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Gardner Syndrome Treatment Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global Gardner syndrome...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
April 24, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Konzernverkäufe stiegen um 2%1 zu konstanten Wechselkursen (CER; -6% in CHF) dank starkem Wachstum der jüngeren Medikamente und Diagnostika; ohne COVID-19-Produkte nahmen die Konzernverkäufe um 7% zu;...
EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight
April 22, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 22, 2024 (GLOBE NEWSWIRE) -- EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the...
BioNTech veröffentlicht am 6. Mai 2024 Ergebnisse für das erste Quartal 2024 und informiert über operativen Fortschritt
April 22, 2024 06:45 ET
|
BioNTech SE
MAINZ, Deutschland, 22. April 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 6. Mai 2024, die Ergebnisse für das erste Quartal 2024...
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
April 22, 2024 06:45 ET
|
BioNTech SE
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024....
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
April 19, 2024 01:00 ET
|
Nykode Therapeutics ASA
OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
April 19, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung...